Physiogenex will be presenting a new DIABETIC NASH HFpEF hamster study at the 83rd Scientific Sessions of the American Diabetes Association in San Diego, CA, USA, June 23-26, 2022.

The poster (#1595-P), entitled “Empagliflozin Improves Nephropathy and Heart Failure with Preserved Ejection Fraction Despite Limited Effects on NASH in a Novel Obese Diabetic Hamster Model” will be presented by Dr. François Briand, our Director of Research and Development, in the Obesity/Integrated Physiology poster session from June Friday the 23rd to Monday June the 26th.

Feel free to contact us if you wish to set-up an appointment with Dr. Briand and/or discuss your drug development projects with us.

About us

 Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.

We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.